[HTML][HTML] Tocilizumab in patients hospitalized with Covid-19 pneumonia
…, B Assman, J Freedman… - … England Journal of …, 2021 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated with
hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and …
hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and …
A review of the evolving landscape of inclusive research and improved clinical trial access
SV Mohan, J Freedman - Clinical Pharmacology & …, 2023 - Wiley Online Library
Current clinical research does not reflect the diversity of patient populations, despite continued
recommendations to increase enrollment of under‐represented racial and ethnic groups. …
recommendations to increase enrollment of under‐represented racial and ethnic groups. …
[HTML][HTML] Advancing inclusive research: establishing collaborative strategies to improve diversity in clinical trials
…, SM Begelman, AS Collins, J Freedman… - Ethnicity & …, 2022 - ncbi.nlm.nih.gov
Well-characterized disparities in clinical research have disproportionately affected patients of
color, particularly in underserved communities. To tackle these barriers, Genentech formed …
color, particularly in underserved communities. To tackle these barriers, Genentech formed …
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor …
118 Background: Niraparib, a highly potent and selective poly (ADP-ribose) polymerase
inhibitor (PARPi) received breakthrough designation by US FDA for treatment of pts with BRCA1,…
inhibitor (PARPi) received breakthrough designation by US FDA for treatment of pts with BRCA1,…
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists
…, T Barrett, G Lagaud, J Freedman… - Journal of medicinal …, 2006 - ACS Publications
A high throughput screening approach to the identification of selective cholecystokinin-2
receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, …
receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, …
Characterization of 2-(2, 6-dichloro-benzyl)-thiazolo [5, 4-d] pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist
…, H Ao, N Swanson, NT Wu, J Freedman… - European journal of …, 2011 - Elsevier
As an integrator of multiple nociceptive and/or inflammatory stimuli, TRPV1 is an attractive
therapeutic target for the treatment of various painful disorders. Several TRPV1 antagonists …
therapeutic target for the treatment of various painful disorders. Several TRPV1 antagonists …
Discovery of potent cholecystokinin-2 receptor antagonists: Elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis
…, C Schubert, L Li, X Wu, J Wu, JM Freedman… - Bioorganic & medicinal …, 2008 - Elsevier
A novel series of cholecystokinin-2 receptor (CCK-2R) antagonists has been identified, as
exemplified by anthranilic sulfonamide 1 (pK i =7.6). Pharmacokinetic and stability studies …
exemplified by anthranilic sulfonamide 1 (pK i =7.6). Pharmacokinetic and stability studies …
Discovery and synthesis of 6, 7, 8, 9-tetrahydro-5H-pyrimido-[4, 5-d] azepines as novel TRPV1 antagonists
…, A Bhattacharya, Q Wang, JM Freedman… - Bioorganic & medicinal …, 2010 - Elsevier
Utilization of a tetrahydro-pyrimdoazepine core as a bioisosteric replacement for a
piperazine-urea resulted in the discovery a novel series of potent antagonists of TRPV1. The …
piperazine-urea resulted in the discovery a novel series of potent antagonists of TRPV1. The …
JNJ-26070109 [(R) 4-bromo-N-[1-(2, 4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor …
MF Morton, TD Barrett, J Freedman, L Li… - … of Pharmacology and …, 2011 - ASPET
… Barrett, Jamie Freedman, Lina Li, Michele C. Rizzolio, Clodagh E. Prendergast, Xiaodong
Wu, Veronica Moreno, Jayashree Pyati, Katherine Figueroa, Laurence Cagnon, Guy Lagaud, …
Wu, Veronica Moreno, Jayashree Pyati, Katherine Figueroa, Laurence Cagnon, Guy Lagaud, …
Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating …
…, T Norman, L Fashoyin-Aje, J Freedman… - JCO Global …, 2022 - ascopubs.org
Patients of African ancestry are not well-represented in cancer clinical trials despite bearing
a disproportionate share of mortality both in United States and Africa. We describe key …
a disproportionate share of mortality both in United States and Africa. We describe key …